Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Will Elon Musk's Tesla be eligible for GOI's PLI scheme?
- ‘The future of Indian entrepreneurship coincides with a shift in the startup story’: Charu Malhotra, Co-founder & CHRO, Primus Partners
- M&A in India: Deals see a resurgence in 2024
- 80% of Indian SMBs rely on online advertising; 76% find it more effective than traditional methods: report
